V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 290006780 | 290005144 | 1.5 | 61.3 | Curative (C) | 2016-04-15 | 2016-04-15 | Carboplatin + Etoposide iv&po | 2 | null | 290020757 | NIVOLUMAB |
| 290006781 | 290005144 | 1.79 | 0 | Curative (C) | 2016-09-14 | 2016-09-17 | PCV | null | N | 290020757 | RITUXIMAB |
| 290006782 | 290005146 | null | 80.8 | Palliative (P) | 2017-11-20 | 2017-11-24 | Cisplatin 100 + RT(H&N) 1 day | N | null | 290020761 | GEMCITABINE |
| 290006783 | 290007166 | 1.76 | null | Curative (C) | 2014-01-03 | 2014-02-07 | CARBOPLATIN + PACLITAXEL | 2 | Y | 290020761 | CISPLATIN + RT |
| 290006784 | 290007166 | 0 | 67.3 | Not known (9) | 2018-12-07 | 2018-12-21 | Sunitinib | 2 | N | 290020761 | CARBOPLATIN + ETOPOSIDE |
| 290006785 | 290005148 | 1.59 | 68 | Adjuvant (A) | null | 2016-06-29 | Capecitabine + Oxaliplatin 14day | 2 | Y | 290020769 | IRINOTECAN |
| 290006786 | 290007168 | 1.68 | null | Palliative (P) | 2017-02-24 | 2017-02-24 | CAPECITABINE + OXALIPLATIN | 02 | N | 290020770 | CAPECITABINE + IRINOTECAN |
| 290006787 | 290007168 | 1.62 | null | Palliative (P) | 2018-05-28 | 2018-06-17 | CARBOPLATIN | null | Y | 290020770 | EVEROLIMUS |
| 290006788 | 290005150 | 1.57 | 67.3 | Palliative (P) | 2016-02-20 | 2016-07-30 | Cetuximab + CISPLATIN + FLUOROURACIL | N | N | 290020777 | PACLITAXEL |
| 290006790 | 290005152 | 1.5 | 54.1 | Curative (C) | 2013-11-17 | 2013-12-02 | Carboplatin + Etoposide IV 3 day | N | N | 290020785 | CETUXIMAB + RT |
| 290006791 | 290005153 | 1.71 | 46 | Curative (C) | 2016-11-01 | 2017-01-11 | FLUOROURACIL + MITOMYCIN | 02 | N | 290020786 | CISPLATIN + RT |
| 290006792 | 290005154 | 1.77 | 77 | Palliative (P) | 2017-05-28 | 2017-06-17 | Carboplatin + Cetux + FU (>Cycle 2) | 02 | Y | 290020787 | BEVACIZUMAB |
| 290006793 | 290005155 | 1.72 | 0 | Adjuvant (A) | 2013-09-26 | 2013-09-29 | LANREOTIDE | 02 | N | 290020790 | CAPECITABINE |
| 290006794 | 290005155 | null | 128.999 | Palliative (P) | 2018-05-30 | 2018-06-11 | Capecitabine + Oxaliplatin 21day | null | N | 290020790 | CISPLATIN + FLUOROURACIL + RT |
| 290006795 | 290005155 | 1.52 | 0 | Palliative (P) | null | 2018-08-08 | Carboplatin AUC 6 - 10 | 02 | null | 290020790 | PACLITAXEL |
| 290006796 | 290005156 | 1.5 | 77.2 | Palliative (P) | 2018-02-24 | 2018-03-10 | Carboplatin + Paclitaxel (3 weekly) | N | N | 290020798 | GEMCITABINE |
| 290006797 | 290005156 | 1.75 | 80.05 | Palliative (P) | 2017-12-04 | 2017-12-04 | Capecitabine (21days) + Carboplatin | 02 | N | 290020798 | PACLITAXEL |
| 290006798 | 290005157 | 1.63 | 117.7 | Curative (C) | 2014-10-18 | 2014-10-28 | Capecitabine | 02 | N | 290020806 | ESHAP |
| 290006799 | 290005158 | 1.72 | 77.2 | null | 2017-12-22 | 2018-01-23 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 290020809 | LANREOTIDE |
| 290006800 | 290005159 | 1.59 | null | Adjuvant (A) | 2015-04-12 | 2015-11-12 | FLUOROURACIL + MITOMYCIN | N | null | 290020816 | CAPECITABINE + OXALIPLATIN |
| 290006801 | 290005160 | 1.81 | 104.7 | Neo-adjuvant (N) | 2014-04-15 | 2014-04-18 | Capecitabine (14 days)+Carboplatin | N | N | 290020820 | CAPECITABINE + MITOMYCIN |
| 290006802 | 290005161 | null | null | null | 2017-12-19 | 2017-12-19 | CETUXIMAB | N | null | 290020824 | LANREOTIDE |
| 290006803 | 290005161 | 1.6 | 108.15 | Palliative (P) | 2016-11-23 | 2016-12-01 | Bortezomib (weekly) | 2 | N | 290020824 | LANREOTIDE |
| 290006804 | 290005162 | 1.61 | 67.7 | Palliative (P) | 2017-08-29 | 2017-09-19 | Dacarbazine | null | N | 290020837 | EOX |
| 290006805 | 290005163 | 1.86 | 55 | Palliative (P) | null | 2018-02-13 | LANREOTIDE | 02 | y | 290020839 | CAPECITABINE + CISPLATIN |
| 290006806 | 290005164 | null | 38.8 | Palliative (P) | 2017-12-14 | 2017-12-28 | Capecitabine | N | null | 290020843 | OCTREOTIDE |
| 290006807 | 290005164 | 0 | 53.6 | Curative (C) | 2013-04-30 | 2013-04-30 | LANREOTIDE | 2 | N | 290020843 | BCG |
| 290006808 | 290005164 | 1.63 | 48 | Adjuvant (A) | 2016-08-29 | 2016-09-14 | OCTREOTIDE | N | N | 290020843 | PACLITAXEL + TRASTUZUMAB |
| 290006809 | 290005167 | null | null | Palliative (P) | null | 2014-04-02 | Bevacizumab + CAPECITABINE + IRINOTECAN | null | N | 290020856 | TRIAL |
| 290006810 | 290005167 | null | 100 | Disease modification (D) | 2017-06-22 | 2017-07-03 | Capecitabine + Cisplatin | 02 | N | 290020856 | STREPTOZOCIN + MDG |
| 290006811 | 290005167 | 1.77 | 0 | Palliative (P) | 2018-04-03 | 2018-04-27 | Trastuzumab + VINORELBINE | N | Y | 290020856 | CAPECITABINE |
| 290006812 | 290005168 | 1.75 | 67.8 | Curative (C) | 2013-01-28 | 2013-10-12 | Capecitabine + Oxaliplatin 14day | N | N | 290020868 | CAP + RT |
| 290006813 | 290007177 | 1.55 | 50.8 | Palliative (P) | 2014-04-05 | 2014-06-15 | Capecitabine + Mitomycin | null | N | 290020874 | CETUXIMAB + CISPLATIN + FU |
| 290006814 | 290005169 | null | 64.9 | Curative (C) | 2015-12-23 | 2016-01-19 | CARBOPLATIN + RT | N | Y | 290020877 | FLUOROURACIL + MITOMYCIN |
| 290006815 | 290005170 | null | null | Palliative (P) | 2018-05-07 | 2018-08-06 | Trial Unspecified | N | N | 290020881 | CARBOPLATIN + PACLITAXEL |
| 290006816 | 290005170 | 1.57 | 75.5 | Palliative (P) | 2014-01-09 | 2014-03-16 | CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL + Trastuzumab | null | N | 290020881 | CAPECITABINE + CISPLATIN + STREPTOZOCIN |
| 290006817 | 290005172 | 1.74 | null | Adjuvant (A) | 2013-04-19 | 2013-04-19 | CISPLATIN + FLUOROURACIL + RT | 2 | N | 290020891 | TRASTUZUMAB |
| 290006818 | 290007987 | 1.87 | null | Palliative (P) | 2015-07-18 | 2015-08-19 | Fluorouracil PVI + Mitomycin 21day | 99 | null | 290020906 | MCX |
| 290006819 | 290005173 | 1.78 | 70.7 | null | 2017-10-31 | 2017-11-07 | Irinotecan | N | N | 290020914 | CAPECITABINE + RT |
| 290006820 | 290005174 | null | 141 | Curative (C) | 2016-08-25 | 2016-09-06 | Capecitabine | N | null | 290020923 | CETUXIMAB |
| 290006821 | 290007180 | 1.74 | 69 | Curative (C) | 2018-03-12 | 2018-04-16 | Sunitinib | N | Y | 290020928 | CAPECITABINE + RT |
| 290006822 | 290007180 | null | 81.6 | Adjuvant (A) | 2014-11-26 | 2014-12-01 | Sunitinib | N | N | 290020928 | CAPECITABINE + OXALIPLATIN |
| 290006823 | 290008478 | 1.77 | 53.6 | null | 2015-05-01 | 2015-10-27 | Sunitinib | N | N | 290020929 | LANREOTIDE |
| 290006824 | 290005175 | 1.5 | 75.4 | Palliative (P) | 2016-03-05 | 2016-06-28 | Trial Unspecified | N | N | 290020932 | IRINOTECAN |
| 290006825 | 290005175 | 1.71 | 66.6 | null | 2017-04-27 | 2017-04-27 | Irinotecan | 02 | null | 290020932 | LANREOTIDE |
| 290006826 | 290005177 | 1.56 | 56.1 | Adjuvant (A) | 2015-06-29 | 2015-12-15 | Cisplatin | null | N | 290020933 | CAPECITABINE + OXALIPLATIN |
| 290006827 | 290005178 | 1.62 | 83.6 | Palliative (P) | 2014-11-18 | 2014-11-25 | Oxaliplatin + Raltitrexed | N | N | 290020957 | SUNITINIB |
| 290006828 | 290005178 | 1.73 | 64.8 | null | 2017-06-18 | 2017-07-14 | PEMBROLIZUMAB | 2 | N | 290020957 | TRASTUZUMAB |
| 290006829 | 290005179 | null | 64.1 | Disease modification (D) | 2017-11-03 | 2017-12-03 | Cetuximab + Radiotherapy Maint | N | N | 290020967 | CARBOPLATIN |
| 290006830 | 290005180 | 1.61 | 61.3 | null | 2016-11-11 | 2016-11-17 | Capecitabine + Oxaliplatin 21day | 02 | N | 290020967 | CETUXIMAB + RT |